FDA Cleared


Transform Your Practice. Schedule a Personalized DermaSensor Demo

Discover how seamlessly DermaSensor integrates into any practice setting, including standalone practices, health systems, walk-in clinics, concierge clinics, and more. Experience firsthand how our cutting-edge AI technology can elevate your practice.

Learn How to
Enhance Your Practice With DermaSensor

Designed with efficiency in mind, DermaSensor ensures rapid, objective test results without compromising quality. Its user-friendly interface makes it effortlessly accessible and easy to incorporate into the busy routine of medical offices. This powerful tool enhances and streamlines physicians’ management process for suspicious skin lesions and translates to tangible value for healthcare systems and payers.

See DermaSensor In action

Get an exclusive, live demonstration of the DermaSensor device. See how our AI-powered device performs skin cancer assessments with unmatched accuracy and ease.

Get Insider Knowledge

Learn how leading physicians are revolutionizing patient care with this new AI tool. Understand how DermaSensor enhances patient experiences, boosts efficiency, and transforms the landscape of skin cancer assessments.

Explore How DermaSensor is Transforming Skin Cancer Assessments

Tell us a bit about your practice so we can tailor your demo to your needs. Book your free personalized demo below.

As Featured In

Bridging the Gap in Skin Cancer Detection: Innovative Solutions for Rapid Diagnosis

Skin cancer is a pervasive and underdiagnosed health concern in the United States, exacerbated by the inefficiencies within the healthcare system. Primary care physicians, who are on the frontline to appropriately treat and triage a host of conditions, have had a lack of adequate diagnostic aids to assess skin lesions. There is an unmet need for tools to improve identification of lesions requiring referral, which may otherwise lead to delayed or missed detection of skin cancer.

Play Video

Key Features

96% sensitivity for detection across all three common skin cancers¹

Proprietary algorithm yields instant assessment.

Ergonomically designed, wireless, and easy to grip.

Always on, ensuring readiness when needed.

How it Works?

Identify lesions suggestive of skin cancer on the patient

Apply handheld DermaSensor device to the lesion and initiate first recording

Five spectral recordings are taken from the skin lesion to complete one scan

DermaSensor's algorithm analyzes spectral data and delivers assessment in seconds


DermaSensor’s tip reflects and records quick bursts of light off the lesion’s cellular and sub-cellular content.

The light is analyzed by the built-in computer to provide information to help physicians assess skin lesions (including melanomas, squamous cell carcinomas, and basal cell carcinomas) to aid in a referral decision.

By examining the difference in light scattering, DermaSensor determines if the skin lesion output is “Monitor” or “Investigate Further,” with the latter result including a 1-10 confidence score for malignancy likelihood.

Elastic Scattering Spectroscopy (ESS) has been validated in 30+ publications on clinical studies for various cancer types. Many studies have shown ESS to provide information that is comparable to histopathologic assessment in the analysis of cellular microscopic structure.

Discover what other practitioners are saying.

Our study indicates that DermaSensor’s ESS device has the potential to enhance the detection of skin malignancies in the primary care setting. This technology not only improved PCPs’ sensitivity for lesion referral but also significantly increased their confidence, both of which are particularly important for non-specialists
Laura Korb Ferris, MD
Professor Of Dermatology And Director Of The University Of Pittsburgh Department Of Dermatology Clinical Trials Unit
This is a rare quadruple win in medicine! It’s a win for the patients, a win for the providers, a win for dermatologists, and a win for insurers. For the patients, it may provide peace of mind with an adjunctive medical device for detecting all three common skin cancers. For the providers, DermaSensor generates an immediate, objective assessment of suspicious skin lesions for timely referrals. For dermatologists, DermaSensor helps prioritize patients requiring a higher level of care and more immediate attention. And for the insurers, this can result in prompt evaluation and treatment if malignancy is detected.
Dr. Kevin Wong, MD
Founder of PT Family Medicine. Past President of the Pennsylvania Academy of Family Physicians
As skin cancer rates continue to rise, the need for accurate and efficient skin cancer detection in primary care is increasingly important. These studies have shown the ESS device benefits physicians, and it is also a non-invasive, easy-to-use solution for instantaneously evaluating suspicious lesions.
Daniel Siegel, MD
Clinical Professor of Dermatology at SUNY Downstate and former President of AAD. Principal Investigator for DermaSensor's FDA Pivotal Clinical Utility Study

Request A Demo

Request A Demo